Sera Prognostics shares surge 14.26% premarket after Jefferies initiates Buy rating with $5 price target, highlighting PreTRM’s market potential.

Sera Prognostics Inc. (NASDAQ:SERA) surged 14.26% in premarket trading following Jefferies’ initiation of coverage with a Buy rating and a $5.00 price target, implying a 42% upside from its $3.51 level. The firm highlighted the company’s PreTRM test—a first-to-market, clinically validated blood test for predicting preterm birth risk—as a key differentiator in a $1.6 billion U.S. addressable market. Jefferies also noted Sera’s partnerships with Elevance and Medicaid pilot programs, alongside its valuation near fair value. While Q3 2025 earnings showed a better-than-expected EPS of -$0.16 versus -$0.23, revenue fell far short at $16,000 vs. $150,000, the stock’s sharp premarket rise aligns with the analyst upgrade, overshadowing mixed financial results. The move reflects investor optimism around Sera’s growth potential in women’s health diagnostics.